Trial reportBone2011
Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women.
Trial report in Bone, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Trial
- Parathyroid hormone 1-84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism.The Journal of clinical endocrinology and metabolism · 2014Trial
- Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014Trial
- Mechanisms limiting the long-term anabolic effects of teriparatide (PTH 1-34) on bone.JBMR plus · 2026Review
- The landscape of aging.Science China. Life sciences · 2022Review
- Effects of parathyroid hormone (1-34) on the regulation of the lysyl oxidase family in ovariectomized mice.RSC advances · 2018Article
- Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.British journal of clinical pharmacology · 2018Review
- Review
- Effect of parathyroid hormone on healing in osteoporotic fractures via a phospholipase C-independent pathway.The Journal of international medical research · 2017Article
- T cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015Article
- Isolation and characterization of human osteoblasts from needle biopsies without in vitro culture.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Article
- Recovery of parathyroid hormone secretion and function in postoperative hypoparathyroidism: a case series.The Journal of clinical endocrinology and metabolism · 2013Article
- Effect of zoledronate on the responses of osteocytes to acute parathyroid hormone.Calcified tissue international · 2013Article
- Article
- Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.The Journal of clinical endocrinology and metabolism · 2012Review
- Osteoporotic fracture and parathyroid hormone.World journal of orthopedics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Intermittent parathyroid hormone (PTH) 1-34 treatment stimulates bone formation, but the molecular mechanisms mediating this effect have not been previously studied in humans. Thus, we used magnetic activated cell sorting to isolate hematopoietic lineage negative (lin-)/alkaline phosphatase positive (AP+) osteoprogenitor cells from bone marrow of 20 postmenopausal women treated with PTH (1-34) for 14 days and 19 control subjects. Serum PINP and CTX increased in PTH-treated subjects (by 97% and 30%, respectively, P<0.001). Bone marrow lin-/AP+ cells from PTH-treated subjects showed an increase in the RANKL/OPG mRNA ratio (by 7.5-fold, P=0.011) and in the mRNAs for c-fos (a known PTH-responsive gene, by 42%, P=0.035) and VEGF-C (by 57%, P=0.046). Gene Set Enrichment Analysis (GSEA, testing for changes in pre-specified pathways) demonstrated that PTH had no effect on osteoblast proliferation, apoptosis, or differentiation markers. However, PTH treatment resulted in a significant decrease (GSEA P-value, 0.005) in a panel of BMP target genes in the lin-/AP+ cells. Our findings thus identify several future directions for studying mechanisms of PTH action in humans. First, given the increasing evidence that PTH induces angiogenesis, the role of increased VEGF-C production by bone marrow osteoprogenitor cells in mediating this effect and the anabolic response to PTH warrants further study. Second, while the observed inhibition of BMP target gene expression by PTH is not consistent with the anabolic effects of PTH on bone and requires further validation, these data do generate the hypothesis that an inhibition of BMP signaling by PTH may, over time, limit the availability of mature osteoblasts on bone surfaces and thereby contribute to the observed waning of the anabolic response to PTH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.